0000880771-16-000173.txt : 20160816
0000880771-16-000173.hdr.sgml : 20160816
20160816144332
ACCESSION NUMBER: 0000880771-16-000173
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160812
FILED AS OF DATE: 20160816
DATE AS OF CHANGE: 20160816
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000880771
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943116852
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
BUSINESS PHONE: 650-358-3456
MAIL ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cheung Wilson Wai-Shun
CENTRAL INDEX KEY: 0001291656
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19825
FILM NUMBER: 161835752
MAIL ADDRESS:
STREET 1: SCICLONE PHARMACEUTICALS, INC.
STREET 2: 950 TOWER LANE, SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
4
1
certent-form4.xml
PRIMARY DOCUMENT
X0306
4
2016-08-12
0000880771
SCICLONE PHARMACEUTICALS INC
SCLN
0001291656
Cheung Wilson Wai-Shun
950 TOWER LANE, SUITE 900
FOSTER CITY
CA
94404
0
1
0
0
CFO & Senior VP, Finance
Common Stock
2016-08-12
4
M
0
25000
0
A
25000
D
Common Stock
2016-08-12
4
M
0
12500
0
A
37500
D
Common Stock
2016-08-12
4
M
0
3000
0
A
40500
D
Common Stock
2016-08-12
4
F
0
9396
10.41
D
31104
D
Common Stock
2016-08-12
4
F
0
1128
10.41
D
29976
D
Common Stock
2016-08-12
4
F
0
4698
10.41
D
25278
D
Common Stock
2016-08-16
4
S
0
7802
10.6174
D
17476
D
Restricted Stock Unit
2016-08-12
4
A
0
30000
0
A
Common Stock
30000
229000
D
Restricted Stock Unit
2016-08-12
4
M
0
25000
0
D
Common Stock
25000
204000
D
Restricted Stock Unit
2016-08-12
4
M
0
12500
0
D
Common Stock
12500
191500
D
Restricted Stock Unit
2016-08-12
4
M
0
3000
0
D
Common Stock
3000
188500
D
Shares disposed represent shares withheld to cover withholding tax obligations in connection with the vesting of Restricted Stock Units.
Granted under the Issuer's 2015 Equity Incentive Plan.
Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock.
Each RSU will vest and be settled on August 15, 2017, subject to the reporting person's continued employment, but will terminate upon the occurrence of a change in control on or before March 31, 2017.
Granted under the Issuer's 2005 Equity Incentive Plan.
Provided Reporting Person remains employed by the Issuer, 33.33% of the restricted stock units vested on January 4, 2016, 33.33% will vest on January 3,2017, and 33.34% will vest on January 2, 2017, unless the trading window is closed for the Reporting Person on such date, in which case the vesting date will be deferred until the next date that the trading window is open.
Provided Reporting Person remains employed by the Issuer, 25% of the restricted stock units will vest on each August 9, 2014, August 9, 2015, August 9, 2016, and August 9, 2017, unless the trading window is closed for the Reporting Person on such date, in which case the vesting date will be deferred until the next date that the trading window is open.
Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.
/s/ Wilson W. Cheung
2016-08-16